Latest Bridge to Life news, funding rounds and robotics & AI coverage. $110M raised. 1 article tracked by The Robotics Media.
Bridge to Life Ltd. is a Northbrook, Illinois-based organ preservation company that develops perfusion and cold-storage solutions used by transplant centres worldwide. Its flagship VitaSmart Hypothermic Oxygenated Perfusion System received U.S. FDA De Novo clearance in January 2026 as the first and only HOPE device authorized for liver transplantation, complementing the company's gold-standard Belzer UW and Belzer MPS UW Machine Perfusion solutions.
The company runs the Bridge to HOPE pivotal clinical trial, an organ viability assessment pipeline and international commercial operations across Europe, India, Saudi Arabia and other CE-mark markets. In August 2026 it closed a $110 million Series C and debt financing to accelerate VitaSmart's US rollout.